Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2009
12/01/2009US7626030 Compounds and methods of use
12/01/2009US7626027 phosphorylation activity; CNS mood disorders (major depressive disorder, bipolar I and II disorders), sleep disorders (circadian rhythm - shift work, jet lag), advanced and delayed sleep phase; reaction of a chloronitropyridine and diethyl malonate; decarboxylation, cyclization
12/01/2009US7626026 Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
12/01/2009US7626025 Isolated from Indian ascidian Synoicum macroglossum by solvent extraction; chromatography; for treatment of diabetic disorders by providing inhibition of alpha (alpha)glucosidase
12/01/2009US7626023 Compounds for treating tumors
12/01/2009US7626014 improved pharmacokinetics; gene silencing; phosphorothioate linkages; naproxen and ibuprofen as ligands
12/01/2009US7626012 Nucleic acids encoding monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CD40; Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
12/01/2009US7626007 Comprises DNA binding polypeptide for prevention and treatment of oral, arthritic, inflammatory, cancer and infectious diseases
12/01/2009US7626005 Antibiotic resistance
12/01/2009US7625950 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
12/01/2009US7625949 administering a drug having formula of 2-[4-chloro-3-(3-chloro-5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro4-sulfamoyl-phenyl)-acetamide for treating an HIV infection
12/01/2009US7625948 Ester that inhibits MTP in intestines as antilipemic agents for side effect reduction
12/01/2009US7625947 5-Lipoxygenase inhibitor for treating inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia; antiinflammatory agent, antitumor agent
12/01/2009US7625945 Andrographolide and analogues as inhibitors of TNFα and IL-1β expression
12/01/2009US7625944 carbamimidoyl benzylamide derivatives; preventing and treating the formation of thrombin during or after a PK dependent disease or condition after fibrinolysis treatment
12/01/2009US7625943 5-alkyl-7-alkylcarbonate-isoflavone ester and related method
12/01/2009US7625942 Method of treating Down syndrome
12/01/2009US7625941 N-substituted pyrrolidinone having a separated pendant ammonium cation by a variable length alkyl spacer and fluoroalkyl sulfonate anions; environmentally friendly solvent; catalysts for reactions, including nitration, acylation, esterification, etherification
12/01/2009US7625940 Method of treating hypertension with a very low dose of chlorthalidone
12/01/2009US7625939 Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors
12/01/2009US7625938 Substituted pyrazoles, compositions containing such compounds and methods of use
12/01/2009US7625937 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
12/01/2009US7625936 Mitotic kinesin inhibitors
12/01/2009US7625935 fungicides; good yields; steps require neither solvents nor reactants that are highly flammable and explosive, carcinogenic or corrosive; 1-chloro-4-chlorophenyl-2-butanol is reacted with the imidazole in toluene and aqueous sodium hydroxide solution in the presence of a phase transfer catalyst
12/01/2009US7625934 Metalloproteinase inhibitors
12/01/2009US7625933 PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent
12/01/2009US7625932 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
12/01/2009US7625931 Certain substituted diphenyl ureas, as modulators of kinase activity
12/01/2009US7625930 Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography
12/01/2009US7625929 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
12/01/2009US7625928 Prevent, therapy of side effect of radiotherapy; applying to skins, mucous membranes
12/01/2009US7625927 Method of treating glaucoma
12/01/2009US7625926 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
12/01/2009US7625925 Pyrazolo[1,5-a]pyridines and medicines containing the same
12/01/2009US7625924 Nicotinic alpha-7 receptor ligands and preparation and uses thereof
12/01/2009US7625923 -4-[7-(hydroxy)-tetrahydro-pyrrolo[1,2-c]oxazol-3-ylideneamino]-2-chloro-3-methyl-benzonitrile; non-steroidal, non-toxic; side effect reduction; aging resistance; sarcopenia, osteoporosis and osteopenia, osteoporosis and osteopenia, cancer cachexia, eating disorders (e.g., anorexia) and chemotherapy
12/01/2009US7625922 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
12/01/2009US7625921 Bridged ring compounds based on nitrogen-containing rings such as 5,10-dihydro-5,10-ethanobenzo(g)quinoline; treating obesity, diabetes and inflammatory or immune associated diseases; nuclear factor kappa beta (NF-KB)
12/01/2009US7625920 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
12/01/2009US7625919 Osteoporosis; oral diseases; bone disorders; atherosclerosis; antiarthritic agents; autoimmune disease; cachexia
12/01/2009US7625918 pure physical form of hydrocodone bitartrate; analgesic agents
12/01/2009US7625917 S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein
12/01/2009US7625916 Medicinal composition
12/01/2009US7625915 treating colon cancer comprising administering N-(1-(4-Methoxyphenyl)-3-tert-butyl-5-pyrazolyl)-N'-(2,3-dichlorophenyl)urea; antitumor, anticarcinogenic, antiproliferative agent; ras protein signal transduction cascade related cancer
12/01/2009US7625914 2(S)-Ethoxy-3-{4-[2-(3-heptyl-1-methylureido)thiazol-4-yl]phenyl}propanoic acid; dermatology, and cardiovascular diseases, immune diseases, lipid metabolism diseases; veterinary medicine
12/01/2009US7625913 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
12/01/2009US7625912 2-Phenylpyrimidinone compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients such as paclitaxel or trastuzumab; side effect reduction
12/01/2009US7625911 Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
12/01/2009US7625910 aurora kinase inhibitor is for the treatment of cancer; 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate; anticarcinogenic agents
12/01/2009US7625909 N-{3-[2-(2-Fluoro-4-methoxyphenyl)-ethyl]-4-oxo-3,4-dihydroquinazolin-7yl}-N-indan-2-yl-3,5-dimethylpiperazine-1-carboxamidine; melanocortin-4 receptor agonists; diabetes
12/01/2009US7625908 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
12/01/2009US7625907 administering a drug of 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, for heart failure and stable angina, cardiovascular disorders
12/01/2009US7625906 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
12/01/2009US7625905 Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists
12/01/2009US7625904 Methods for the treatment of sleep disorders
12/01/2009US7625903 Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide
12/01/2009US7625902 improved pharmacological properties like metabolic stability, selectivity, bioavailability and activity; Liver-X-Receptors modulators; to treat increased lipid and cholesterol levels; 4-[4-(2,5-Dimethyl-phenyl)-piperazine-1-carbonyl]-1-(3-methoxy-benzenesulfonyl)-3-phenyl-imidazolidin-2-one
12/01/2009US7625901 for treating migraine, headaches; 2-[(8S)-8-(3,5-Difluorophenyl)-6-oxo-7-azaspiro[4.5]dec-7-yl]-N-(2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2-yl)acetamide
12/01/2009US7625900 Analgesics; potassium channel moderators; headaches; antiepileptic agents; psychological disorders; incontinence; neuropathic pain
12/01/2009US7625899 antiproliferative, antitumor and anticarcinogenic agent; cyclin dependent kinase inhibitor
12/01/2009US7625897 5-[6-Chloro-2-fluoro-3-((R)-5-methyl-6-oxo-1,4,5,6-tetrahydro-[1,2,4]triazin-3-ylmethyl)-phenoxy]-isophthalonitrile; contacting a phenylacetic acid compound with an amino acid ester in presence of a coupling reagent to produce an intermediate, then with Lawesson's reagent, finally with hydrazine; AIDS
12/01/2009US7625896 Pyridylsulfonamide derivatives
12/01/2009US7625895 e.g. 5-[rac-cis-2,3-Bis-(4-chloro-phenyl)-5-oxo-2,3-dihydro-5H-imidazo[1,2-a]pyridine-1-sulfonyl]-2-fluoro-benzonitrile; inhibit the interaction of tumor suppressor MDM2 protein with a p53-like peptide; antiproliferative agent; cycle arrest in G1 and G2 phase
12/01/2009US7625894 Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors
12/01/2009US7625893 (3S,4R,5R)-3-hydroxymethyl-4-[4-((S)-3-methoxy-2-methyl-propoxymethyl)-phenyl]-5-[4-(3-methoxy-propyl)-3,4-dihydro-2H-benzo [1,4]oxazin-6-ylmethoxy]-piperidine-1-carboxylic acid benzyl ester; improvement of the pharmacokinetic properties; better bioavailability
12/01/2009US7625892 Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/01/2009US7625891 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease
12/01/2009US7625890 Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
12/01/2009US7625889 Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
12/01/2009US7625888 {(1R)-1-(2,4,5-Trifluorobenzyl)-2-[9-(trifluoromethyl)-5,6-dihydrobis[1,2,4]triazolo[1,5-a:3',4'-c]pyrazin-3-yl]ethyl}amine, hydrochloride; metformin; treating non-insulin dependent (Type 2) diabetes in a mammal
12/01/2009US7625887 e.g. 2-[3,5-trans-5-(3-aminophenyl)-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide; G-protein-coupled receptor (TGR5) agonist; central nervous system diseases; antiinflammatory agent; learning enhancement; angina pectoris, arrhythmia, bronchial asthma
12/01/2009US7625886 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
12/01/2009US7625885 administering Palmerolides, macrocyclic polyketides bearing carbamate and a vinyl amide or aldehyde functionality; extracts from the tunicate Synoicum adareanum, used for treatment of melanoma, colon and renal cancer; anticarcinogenic agents
12/01/2009US7625884 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
12/01/2009US7625883 Choline Salt of L- alpha -glycero-phospho-D-mio-inositol; alpha -glycero-phospho-D-mio-inositol tetrabutylammonium salt; treatment of pathologies mediated by the activation or over stimulation of cytololilc phospholipase-2 (PLA2), particularly, septic shock and viral and bacterial infections
12/01/2009US7625882 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
12/01/2009US7625881 3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methyl butanoate; treatment of asthma and diarrhea
12/01/2009US7625880 2-(4-fluoro-2-methylphenylamino)-1,6-dimethyl-7-[3-(4-methyl-4-oxo-4 lambda 5[1,4]azaphosphinan-1-yl)-propenyl]-1,8-dihydro-imidazo[4,5-h]isoquinolin-9-one; anticancer agents, antiinflammatory agents, antiviral agents, anti-thromboembolic agents, as well as for treating autoimmune disease
12/01/2009US7625879 Phosphohalohydrins, process for the production thereof and use thereof
12/01/2009US7625878 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
12/01/2009US7625877 Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase
12/01/2009US7625876 Reducing toxicity associated with 6-mercaptopurine drug treatment via monitoring concentration of 6-thioguanine in blood; treating inflammatory bowel disease
12/01/2009US7625875 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
12/01/2009US7625872 a branch-point nucleoside to which three core nucleic acid moieties are covalently coupled; therapy for cancer and Th2-type immune response (e.g., an allergy or allergy-induced asthma) by increasing the secretion of interferon-gamma
12/01/2009US7625871 e.g. 5,6-Dichloro-2-dimethylamino-3-formyl-1-(2,3-O-isopropylidene- beta -D-ribofuranosyl)indole; cytomegalovirus infection, hepatitis B virus infection, herpes simplex virus type 1 infection, varicella zoster virus infection, Epstein Barr virus infection, human herpes virus ;
12/01/2009US7625861 Copolymer-1 improvements in compositions of copolymers
12/01/2009US7625860 Administering a combination of a cytotoxic agent and a fibroblastic growth factor antagonist, wherein the FGF antagonist enhances the efficacy of the cytotoxic agent
12/01/2009US7625751 WNV core protein/capsid interacting protein and uses of the same
12/01/2009US7625750 Compositions for DNA mediated gene silencing
12/01/2009US7625710 Methods for determining 2F1-binding compounds
12/01/2009US7625696 Method and screening kit using a GPR30 receptor and a ligand capable of specifically binding to receptor, a compound which is obtainable using screening method or kit; particularly relates to screening method and screening kit for prevention/treatment of cancer, heart disease
12/01/2009US7625583 Microbiocidal fatty acids such as palmitoleic acid and lauric acid
12/01/2009US7625582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
12/01/2009US7625581 Porous substrate comprising a biodegradable, hydrophobic polymer and a hyaluronic acid complex incorporated with the substrate, wherein the hyaluronic acid complex is insoluble in water, yet soluble in mixtures of organic and aqueous solvents in which the hydrophobic polymer is soluble
12/01/2009US7625579 A substrate having a vapor deposited furanone compounds, covalent bonding through etherification or amination; protective coatings on medical equipment, seeds, fibrics, wool, hair, silk, cotton, chitin, collagen, animal
12/01/2009US7625561 Diabody which specifically binds Streptococcus surface antigen I/II and methods of use thereof
12/01/2009US7625554 Treatment of alzheimer's disease
12/01/2009US7625552 Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces
12/01/2009US7625548 Methods and apparatus for producing nanoscale particles
12/01/2009US7625507 Extrusion/melt-congeal process; reduced drug degradation